These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34863788)

  • 1. The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients.
    Bohaumilitzky L; Kluck K; Hüneburg R; Gallon R; Nattermann J; Kirchner M; Kristiansen G; Hommerding O; Pfuderer PL; Wagner L; Echterdiek F; Kösegi S; Müller N; Fischer K; Nelius N; Hartog B; Borthwick G; Busch E; Haag GM; Bläker H; Möslein G; von Knebel Doeberitz M; Seppälä TT; Ahtiainen M; Mecklin JP; Bishop DT; Burn J; Stenzinger A; Budczies J; Kloor M; Ahadova A
    Gastroenterology; 2022 Mar; 162(3):907-919.e10. PubMed ID: 34863788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
    Bajwa-Ten Broeke SW; Ballhausen A; Ahadova A; Suerink M; Bohaumilitzky L; Seidler F; Morreau H; van Wezel T; Krzykalla J; Benner A; de Miranda NF; von Knebel Doeberitz M; Nielsen M; Kloor M
    Exp Mol Pathol; 2021 Oct; 122():104668. PubMed ID: 34302852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic abnormalities precede microsatellite instability in lynch syndrome-associated colorectal tumourigenesis.
    Pussila M; Laiho A; Törönen P; Björkbacka P; Nykänen S; Pylvänäinen K; Holm L; Mecklin JP; Renkonen-Sinisalo L; Lehtonen T; Lepistö A; Linden J; Mäki-Nevala S; Peltomäki P; Nyström M
    EBioMedicine; 2024 May; 103():105111. PubMed ID: 38583260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lynch Syndrome: Its Impact on Urothelial Carcinoma.
    Lindner AK; Schachtner G; Tulchiner G; Thurnher M; Untergasser G; Obrist P; Pipp I; Steinkohl F; Horninger W; Culig Z; Pichler R
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
    Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic analysis of 45 patients with suspected Lynch syndrome using next-generation sequencing].
    Yao ZG; Cheng XK; Lin CH; Li J; Lyu BB; Li JM; Jing HY; Qin YJ; Sun XC
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):843-849. PubMed ID: 34407589
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.
    Bolivar AM; Duzagac F; Sinha KM; Vilar E
    Mol Aspects Med; 2023 Oct; 93():101204. PubMed ID: 37478804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correspondence on "Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database" by Dominguez-Valentin et al.
    Chambuso R; Kaambo E; Rebello G; Ramesar R
    Genet Med; 2022 May; 24(5):1148-1150. PubMed ID: 35168886
    [No Abstract]   [Full Text] [Related]  

  • 9. Multi-omic analysis in normal colon organoids highlights MSH4 as a novel marker of defective mismatch repair in Lynch syndrome and microsatellite instability.
    Devall M; Ali MW; Eaton S; Weisenberger DJ; Reilley MJ; Powell SM; Li L; Casey G
    Cancer Med; 2023 Jun; 12(12):13551-13572. PubMed ID: 37162286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair protein status of non-neoplastic uterine and intestinal mucosa in patients with Lynch syndrome and double somatic mismatch repair protein mutations.
    Freitag CE; Chen W; Pearlman R; Hampel H; Stanich PP; Cosgrove CM; Konnick EQ; Pritchard CC; Frankel WL
    Hum Pathol; 2023 Jul; 137():1-9. PubMed ID: 37030500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLH1 Exon 12 Gene Deletion Leading to Lynch Syndrome: A Case Report.
    Cui S; Zhang X; Zou R; Ye F; Wang Y; Sun J
    Oncol Res Treat; 2021; 44(7-8):414-421. PubMed ID: 34091457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X.
    Bucksch K; Zachariae S; Ahadova A; Aretz S; Büttner R; Görgens H; Holinski-Feder E; Hüneburg R; Kloor M; von Knebel Doeberitz M; Ladigan-Badura S; Moeslein G; Morak M; Nattermann J; Nguyen HP; Perne C; Redler S; Schmetz A; Steinke-Lange V; Surowy H; Vangala DB; Weitz J; Loeffler M; Engel C;
    Int J Cancer; 2022 Jan; 150(1):56-66. PubMed ID: 34469588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch Syndrome in Thai Endometrial Cancer Patients.
    Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
    Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention.
    Bolivar AM; Duzagac F; Deng N; Reyes-Uribe L; Chang K; Wu W; Bowen CM; Taggart MW; Thirumurthi S; Lynch PM; You YN; Rodriguez-Pascual J; Lipkin SM; Kopetz S; Scheet P; Lizee GA; Reuben A; Sinha KM; Vilar E
    Gastroenterology; 2024 May; 166(5):787-801.e11. PubMed ID: 38244726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients.
    Yu JH; Xiao BY; Tang JH; Li DD; Wang F; Ding Y; Han K; Kong LH; Ling YH; Mei WJ; Hong ZG; Liao LE; Yang WJ; Pan ZZ; Zhang XS; Jiang W; Ding PR
    Eur J Cancer; 2023 Oct; 192():113253. PubMed ID: 37625240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironment profiling of normal appearing colorectal mucosa biopsied over repeat patient visits reproducibly separates lynch syndrome patients based on their history of colon cancer.
    Brand RM; Dudley B; Karloski E; Zyhowski A; Raphael R; Pitlor D; Metter EJ; Pai R; Lee K; Brand RE; Uttam S
    Front Oncol; 2023; 13():1174831. PubMed ID: 37637062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry.
    Laurino MY; Truitt AR; Tenney L; Fisher D; Lindor NM; Veenstra D; Jarvik GP; Newcomb PA; Fullerton SM
    Mol Genet Genomic Med; 2017 Nov; 5(6):700-708. PubMed ID: 29178651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of genetic testing by the children of Lynch syndrome variant carriers across three generations.
    Seppälä TT; Pylvänäinen K; Mecklin JP
    Eur J Hum Genet; 2017 Nov; 25(11):1237-1245. PubMed ID: 28832568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.
    Drescher KM; Sharma P; Lynch HT
    Clin Dev Immunol; 2010; 2010():170432. PubMed ID: 20631828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch Syndrome colorectal mucosa.
    Bowen CM; Deng N; Reyes-Uribe L; Parra ER; Rocha P; Solis LM; Wistuba II; Sepeda VO; Vornik L; Perloff M; Szabo E; Umar A; Sinha KM; Brown PH; Vilar E
    Front Immunol; 2023; 14():1162669. PubMed ID: 37207208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.